Alzheimer’s Plaque VANISHES After Treatment— Doctors Stunned

A Texas woman who once could barely recall her own address says the brain plaques tied to her Alzheimer’s disease have vanished from her scans, and now she is sharing that story with the country.

Quick Take

Gail Youngdale, a Dallas-area Alzheimer’s patient, says amyloid plaque no longer shows up on her brain scans after treatment with the drug lecanemab, sold as Leqembi.
Her daughter, Teri Youngdale, says the plaque has stayed gone and has not come back.
Youngdale is now featured in a national BrightFocus Foundation campaign meant to raise awareness about Alzheimer’s research.
Medical research on lecanemab shows it can clear or greatly reduce amyloid plaque, but the drug’s effect on memory and daily function is smaller and slower to appear.

A Second Chance After a Tough Diagnosis

KSAT first told Youngdale’s story in 2023, when she was living with progressive Alzheimer’s disease. She had just started lecanemab, an experimental drug at the time, sold under the brand name Leqembi. Three years later, KSAT reports Youngdale has remarried, regained a sense of independence, and now serves as a face for a national push to fight the disease.

Her daughter, Teri Youngdale, told KSAT the amyloid plaque tied to her mother’s disease no longer shows up on brain scans. She described the change as lasting, saying the plaque has not returned since it cleared. The family’s account is now part of BrightFocus Foundation’s “Stop Alzheimer’s Disease” campaign, launched during World Alzheimer’s Month to spread awareness and push people to protect their brain health.

What the Drug Is Designed to Do

Lecanemab targets amyloid, a sticky protein that builds up in the brains of Alzheimer’s patients and is believed to damage memory and thinking over time. The U.S. Food and Drug Administration’s own review found the drug cut brain amyloid plaque in a dose- and time-based pattern, with a statistically significant drop compared to patients given a placebo. A major clinical trial found similar results, and BrightFocus notes the FDA has since expanded approval to include an at-home injectable version of the drug.

Plaque Loss Does Not Always Mean Full Recovery

Large studies back up the idea that lecanemab can clear amyloid dramatically. One systematic review found 81% of patients in a major trial reached amyloid-negative scan results. But doctors caution that clearing plaque and reversing symptoms are two different things. The same trial data showed lecanemab slowed cognitive decline by about 27%, a real but modest benefit, not a cure, over an 18-month study period.

An independent cost-effectiveness review found the amyloid reduction was strong and statistically clear, but the effect on daily function scores, while measurable, did not reach the same level of certainty in every measure. That gap matters for families weighing whether the drug’s benefits are worth its risks and its price, especially as more patients like Youngdale seek treatment through their own doctors.

Why Her Story Resonates Nationally

Alzheimer’s disease has no cure, and families across the country spend years watching loved ones lose their memories with few treatment options. Youngdale’s willingness to share her results publicly gives other patients and caregivers a real example of what current treatment can look like, both the hope it offers and the questions that remain about how long the benefits last. BrightFocus has built out podcasts, webinars, and patient resources around drugs like Leqembi to help families understand their options.

For many readers watching health care costs and access debates play out in Washington, stories like Youngdale’s carry weight beyond one family’s relief. Newer Alzheimer’s treatments remain expensive and require regular brain scans to monitor for side effects, putting them out of reach for some patients even as the science advances. Her case shows real progress is possible, while research groups continue pushing to make that progress affordable and available to more people.